| ISSN |
2218-4333 (online) |
| Open Access |
This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/ |
| Copyright |
© The Author(s) 2025. Published by Baishideng Publishing Group Inc. All rights reserved. |
| Article Reprints |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
|
| Permissions |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
|
| Publisher |
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA |
| Website |
http://www.wjgnet.com |
| Category |
Oncology |
| Manuscript Type |
Meta-Analysis |
| Article Title |
Ropeginterferon Alfa-2b vs standard therapy in polycythemia vera: A meta-analysis of efficacy and safety outcomes
|
| Manuscript Source |
Unsolicited Manuscript |
| All Author List |
Leo Tom, Shinjit Mani, Akash Rawat, Mina Nan, Shruti Manoj Mundada, Basel Al Khatib, Aparna Gopinath, Osama Taj, Namitha Salahuddin, farzana shaju, Syeda Parsa, Mahmud Abdurrahman, Ashesh Das, Mirza Muhammad Hadeed Khawar and Ali Sher |
| ORCID |
|
| Funding Agency and Grant Number |
|
| Corresponding Author |
Ali Sher, MD, Department of Clinical Oncology, International University of Kyrgyzstan, ISM IUK Eastern Campus, Bishkek, Kyrgyzstan, 1F Intergelpo Street, Bishkek 720054, Kyrgyzstan, Bishkek 720054, Chüy, Kyrgyzstan. aligondal78679@gmail.com |
| Key Words |
Polycythemia vera; Ropeginterferon alfa-2b; Hydroxyurea; Hematologic response; Molecular response; Adverse events |
| Core Tip |
Ropeginterferon alfa-2b significantly enhances complete hematologic and molecular responses in polycythemia vera compared to standard therapy, reducing phlebotomy needs without increasing thrombotic risk. However, higher adverse event-related discontinuations necessitate careful patient monitoring. Despite robust study designs, heterogeneity and potential publication bias warrant cautious interpretation. Long-term studies are essential to refine dosing and improve tolerability for optimal patient outcomes. |
| Publish Date |
2025-10-24 06:10 |
| Citation |
<p>Tom L, Mani S, Rawat A, Nan M, Mundada SM, Al Khatib B, Gopinath A, Taj O, Salahuddin N, shaju F, Parsa S, Abdurrahman M, Das A, Khawar MMH, Sher A. Ropeginterferon Alfa-2b vs standard therapy in polycythemia vera: A meta-analysis of efficacy and safety outcomes. <i>World J Clin Oncol</i> 2025; 16(10): 112392</p> |
| URL |
https://www.wjgnet.com/2218-4333/full/v16/i10/112392.htm |
| DOI |
https://dx.doi.org/10.5306/wjco.v16.i10.112392 |
